LAG3 and neoplasm: Moreover, preclinical studies demonstrate that IBI323, a bispecific antibody against PD-L1/LAG-3, improves tumor-specific immunity, suggesting that dual-blockade bispecific antibodies targeting PD-L1 and LAG-3 may represent a viable treatment option (81).